Rising Prevalence of Antimicrobial Resistance in Urinary Tract Infections During Pregnancy: Necessity for Exploring Newer Treatment Options

Meher Rizvi, Fatima Khan, Indu Shukla, Abida Malik, Shaheen
Departments of Microbiology, Obstetrics and Gynaecology, JNMCH, AMU, Aligarh 202 002, India

Address for correspondence: Dr. Meher Rizvi, E-mail: rizvimeher@yahoo.co.in

ABSTRACT

Background: Urinary tract infections (UTI) are one of the most common medical complications of pregnancy. The emergence of drug resistance and particularly the Extended-spectrum beta-lactamase production by *Escherichia coli* and methicillin resistance in *Staphylococci*, limits the choice of antimicrobials.

Materials and Methods: Patients in different stages of pregnancy with or without symptoms of urinary tract infection attending the antenatal clinic of obstetrics and gynaecology were screened for significant bacteriuria, by standard loop method on 5% sheep blood agar and teepol lactose agar. Isolates were identified by using standard biochemical tests and antimicrobial susceptibility testing was done using Kirby Bauer disc diffusion method.

Results: A total of 4290 (51.2%) urine samples from pregnant females showed growth on culture. Prevalence of asymptomatic bacteriuria 3210 (74.8%) was higher than symptomatic UTI 1080 (25.2%). *Escherichia coli* was the most common pathogen accounting for 1800 (41.9%) of the urinary isolates. Among the gram-positive cocci, coagulase negative species of *Staphylococci* 270 (6.4%) were the most common pathogen. Significantly high resistance was shown by the gram negative bacilli as well as gram positive cocci to the β-lactam group of antimicrobials, fluoroquinolones and aminoglycosides. Most alarming was the presence of Extended-spectrum beta-lactamase in 846 (47%) isolates of *Escherichia coli* and 344 (36.9%) isolates of *Klebsiella pneumoniae*, along with the presence of methicillin resistance in 41% of *Staphylococcus* species and high-level aminoglycoside resistance in 45(30%) isolates of *Enterococcus* species. Glycopeptides and carbepenems were the only group of drugs to which all the strains of gram positive cocci and gram negative bacilli were uniformly sensitive, respectively.

Conclusions: Regular screening should be done for the presence of symptomatic or asymptomatic bacteriuria in pregnancy and specific guidelines should be issued for testing antimicrobial susceptibility with safe drugs in pregnant women so that these can be used for the treatment. For empirical treatment cefoperazone-sulbactum can be recommended, which is a safe drug, covering both gram positive and gram negative organisms and with a good sensitivity.

Keywords: Antimicrobial resistance, extended-spectrum beta-lactamase, high-level aminoglycoside resistance, MRSA, pregnancy, urinary tract infection

INTRODUCTION

Urinary tract infections (UTIs) are one of the most common medical complications of pregnancy. Untreated upper UTI in pregnancy carries well documented risk of morbidity and rarely, mortality to the pregnant women.[1] Pregnancy causes numerous hormonal and mechanical changes in the body. Beginning in the sixth week, with peak incidence during 22nd to 24th weeks, 90% of the pregnant females develop uretral dialatation increasing the risk of urinary stasis and vesicouretral reflux. In addition, glycosuria and aminoaciduria during pregnancy provide an excellent culture medium for bacteria in areas of urinary stasis.[2] These changes along with already short urethra and difficulty with hygiene due to the distended pregnant belly increase the frequency of UTI in pregnant females. Untreated bacteriuria in pregnancy either asymptomatic or symptomatic is associated with a 50% increase in the risk of low birth weight and a significant increase in the risk of premature delivery,[3] pre-eclampsia,[4] hypertension, anemia,[5] and postpartum endometritis.[6]

A limited and predictable spectrum of organisms
causes UTI in pregnant otherwise healthy females. *Escherichia coli* is the primary urinary tract pathogen accounting for 75%--90% of uncomplicated UTI isolates. Other uropathogens include *Staphylococcus saprophyticus* in 5%--10% episodes and *Klebsiella pneumoniae*, *Proteus mirabilis* and group B *Streptococci* in less than 5%. Because of altered pharmacokinetics, drug use in pregnancy may have unpredictable effects. Certain antibiotics are unsuitable for use due to their potential toxicity. Antimicrobial agents considered safe in pregnancy are nitrofurantoin, β-lactam antibiotics including both penicillins and cephalosporins and fosfomycin trometamol. However, the emergence of drug resistance and particularly the ESBL production by *Escherichia coli* and methicillin resistance in *Staphylococcus species*, limits the choice of antimicrobials. This prospective study was designed to find out the prevalence of various organisms in UTI among the pregnant females and their antimicrobial resistance pattern and to review the drugs that can be used for the treatment of the same.

**MATERIALS AND METHODS**

The study was conducted prospectively in the Department of Microbiology, Jawaharlal Nehru Medical College and Hospital, AMU Aligarh from June 2002 to June 2007. Consecutive patients in different stages of pregnancy with or without symptoms of urinary tract infection attending the antenatal clinic of Obstetrics and Gynaecology were screened for significant bacteriuria, by standard loop method on 5% sheep blood agar and teepol lactose agar. Significant bacteriuria is defined as two consecutive positive cultures of >10° cfu/ml of midstream urine with growth of the same species. For pregnant women with symptoms, a diagnostic criterion of >10³ organisms/ml of midstream urine in a single culture was taken as significant bacteriuria. Non-pregnant females and those on antimicrobial therapy for UTI or for any other illness were excluded from the study. Inadequate urine samples (less than 10 ml urine), urine bag collected specimens, specimens collected more than 2 h before, specimens submitted in leaking or dirty unsterile containers and specimens revealing growth of more than two types of bacteria on culture were also excluded from the study.

Isolates in significant numbers were identified by using standard biochemical tests. Antimicrobial susceptibility testing was done for all the isolates using Kirby Bauer disc diffusion method as recommended by CLSI M2-A9. The antibiotic panels for each group of isolates were selected according to the CLSI guidelines M100-S16.

Among the gram positive cocci the antimicrobials tested for *Staphylococcal* species were oxacillin (1 µg), amoxicillin (30 µg), gentamicin (10 µg), ampicillin (10 µg), clindamycin (2 µg), and vancomycin (30 µg). For *streptococcus* species the antimicrobials tested were amoxicillin (30 µg), gentamicin (10 µg), erythromycin (15 µg), high content gentamicin (120 µg), high content streptomycin (300 µg), and vancomycin (50 µg). Oxacillin (1 µg) for the detection of *Methicillin*-resistant *S. aureus* (MRSA) and 120 µg gentamycin and 300 µg streptomycin disc for detection of high level resistance to aminoglycosides (HLAR) in *Enterococci*.

**Statistical analysis**

Statistical analysis was done using chi-square test and Student’s *t*-test.

**RESULTS**

During the five-year study period, a total of 8379 urine samples of pregnant females were collected out of which 4290 (51.2%) showed growth on culture. Majority of the patients showing growth on culture had asymptomatic bacteriuria 3210 (74.8%), while symptomatic UTI was present in only 1080 (25.2%) of the pregnant females (*P* value < 0.001, CI 95% and the degree of freedom is 1). Most of the patients with symptomatic UTI complained of increased frequency and burning during micturition along with urgency. Fever was present in just a limited number of patients. Most of the patients with symptomatic as well as asymptomatic UTI were in the first trimester of pregnancy 2296 (53.5%), followed by third trimester 1909 (44.5%), and only 85 (1.98%) had bacteriuria in the second trimester of pregnancy.

99
Microbiology

The Enterobacteriaceae accounted for nearly two-third of the isolates 3315 (77.3%) and Escherichia coli alone accounted for 1800 (41.9%) of the urinary isolates, followed by Klebsiella pneumoniae 930 (21.7%), Citrobacter species 315 (7.3%) [C. koseri 298(94.6%) isolates, C. amalonaticus 10 (3.2%), C. freundii 7 (2.2%)] and Proteus mirabilis and Proteus vulgaris together accounting for 270 (6.3%) isolates. In 150 (3.4%) urinary specimens Pseudomonas aeruginosa and other Pseudomonas species were isolated. Among the gram positive cocci, Coagulase negative Staphylococci were the predominant isolate accounting for 270 (6.4%) of the cases of UTI. On novobiocin sensitivity testing 74.1% (200) of the coagulase negative isolates were Staphylococcus saprophyticus and 25.9% (70) isolates were Staphylococcus epidermidis. S. aureus 255(5.94%), Enterococcus faecalis 150 (7.34) and Streptococcus species 150 (7.3%) [Table 1].

Antimicrobial resistance

The resistance rates among the gram negative and gram positive isolates are given in Tables 2 and 3, respectively.

Penicillins and cephalosporins

A significantly high resistance was noted to the β-lactam group of antimicrobials both by the gram negative bacilli as well as the gram positive cocci. Nearly half of the isolates of the Enterobacteriaceae, i.e., 1698 (51.2%) and 96 (64.3%) of the Pseudomonas isolates were resistant to cefotaxime, a third generation cephalosporin. However, cefoperazone-sulbactam (a combination of third generation cephalosporin with β lactamase inhibitor) was found to be a better drug with sensitivity of around 90% (3056) isolate of Enterobacteriaceae and 86% (128) of Pseudomonas isolates. 846 (47%) isolates of Escherichia coli and 344 (36.9%) isolates of Klebsiella pneumoniae were found to be ESBL producers. 331 (10%) of the isolates of Enterobacteriaceae were found to be Amp C producers. However, none of the isolates were found to produce metallo-β-lactamas.

Amongst the gram positive cocci, 92 (34%) isolates of Coagulase negative Staphylococcus species and 87 (34.1%) Staphylococcus aureus (MRSA) isolates were resistant to oxacillin. All the strains of Staphylococcus species resistant to oxacillin were considered resistant to all the other β-lactam antimicrobials including cephalosporins and carbapenems. Significantly low resistance was noted for amoxycillin 15 (10%) by the Enterococcus faecalis.

Flouroquinolones

Flouroquinolones had a poor activity against the Enterobacteriaceae as well as on other gram negative and also on gram positive isolates. Gatifloxacin was better than the other flouroquinolones, with 2066 (62.3%) of the Enterobacteriaceae isolates and 106 (69.8%) of the Pseudomonas isolates showing resistance. Around two-third isolates of S. aureus 189 (74.1%) and of Coagulase negative Staphylococcus species 197 (72.9%) were resistant to gatifloxacin.

Nitrofurantoin

It was found have a good sensitivity profile with just 1326 (40%) Enterobacteriaceae, and 94 (36.8%) S. aureus and 91 (33.7%) isolates of CONS showing resistance to the same.

Aminoglycosides

Amikacin had a better spectrum of antimicrobial sensitivity, with resistance to just 630 (19%) of the isolates of Enterobacteriaceae and 54 (35.8%) of the Pseudomonas isolates. However, the resistance to aminoglycosides was higher among the gram positive cocci 151(59.2%) in Staphylococcus aureus and 162 (60%) in CONS. On testing with high content gentamycin and high content streptomycin 45 (30%) of Enterococcus faecalis were found to have high-level aminoglycoside resistance (HLAR).

Carbapenems and glycopeptides

All the gram negative and all the gram positive isolates were uniformly sensitive to carbapenems and glycopeptides, respectively.

DISCUSSION

The study was conducted to evaluate the prevalence of UTI in pregnant females and to review the drugs that can
be used for the treatment of the same. During the five-year study period, a total of 4290 samples of urine from pregnant females, in different stages of pregnancy were found to be positive on culture. The prevalence of asymptomatic bacteriuria was higher (nearly two-third of the total; 74.8%) than symptomatic UTI (25.2%). Females in the first and third trimester of pregnancy had greater incidence of asymptomatic as well as symptomatic bacteriuria.

The gram negative bacteria predominated, with *Escherichia coli* being the most common pathogen (41.9%) isolated in the study. Other studies had also reported a similar frequency of UTI caused by *Escherichia coli*. Amongst the gram positive cocci, CONS were isolated most frequently (6.4%), followed by Staphylococcus aureus (5.9%), *Enterococcus faecalis* (3.5%), and Streptococcus species (3.5%). However, other authors have reported *S. aureus* as the most common urinary pathogen among the gram positive cocci followed by other Staphylococcus species.

On antimicrobial susceptibility testing, it was noted that both the gram negative bacilli as well as the gram positive cocci showed a significantly high resistance to the β-lactam group of antimicrobials which are considered the traditional drugs safe in pregnancy. There are similar reports of high level resistance in the general population to these drugs by the urinary pathogens. Along with this the presence of extended spectrum-β-lactamases in about half of *E. coli* isolates and around 37% of *Klebsiella* was noted, which is a cause for worry. In a study from PGI Chandigarh on complicated UTI, ESBL production was noted in a similar frequency. Among the gram positive cocci, nearly one-third isolates of *S. aureus* and Coagulase negative Staphylococcus species were found to be methicillin resistant. This is an alarming finding, since these isolates should be considered resistant to all the other currently available β-lactam antimicrobials including cephalosporins and carbapenems. Moreover, the methicillin resistant strains of Staphylococci are found to be multidrug resistant as reported by other studies. This further restricts the treatment options. Although the usage of β lactam antimicrobials is considered safe in pregnancy, the resistance to these drugs, by the common pathogens is alarmingly very high as seen in our study which restricts their use to only the sensitive strains.

Among the fluoroquinolones least resistance was exhibited to gatifloxacin, but still it was as high as 62%. Other studies have also reported high resistance to fluoroquinolones, to even the newer ones such as ofloxacin and pefloxacin. This may be due to the overuse of these drugs. Second, fluoroquinolones are not considered safe in pregnancy. Nitrofurantoin, a urinary antiseptic, was found to have a better susceptibility. Though considered safe by some authors, nitrofurantoin had been reported to increase the risk of haemolysis and glucose-6-phosphate

### Table 2: Antimicrobial susceptibility pattern of gram negative organisms isolated from urine

| Antimicrobials tested | Enterobacteriaceae n = 3315 | Pseudomonas species n = 250 |
|-----------------------|-----------------------------|-----------------------------|
|                       | Sensitive no. (%) | Resistant no. (%) | Sensitive no. (%) | Resistant no. (%) |
| Amikacin              | 256 (81.1)        | 630 (19)           | 96 (64.2)        | 54 (35.8)         |
| Cefotaxime            | 1627 (48.8)       | 1698 (31.2)        | 54 (35.7)        | 96 (64.3)         |
| Cefoperazone-sulbactum| 3056 (92.2)       | 259 (7.8)          | 128 (85.7)       | 22 (14.3)         |
| Ciprofloxacin         | 2176 (35.5)       | 2319 (64.5)        | 22 (14.2)        | 128 (85.8)        |
| Gatifloxacin          | 1249 (37.7)       | 2066 (62.3)        | 44 (30.2)        | 106 (69.8)        |
| Gentamicin            | 2134 (64.4)       | 1182 (35.6)        | 64 (42.8)        | 86 (57.2)         |
| Imipenem              | 335 (100)         | 0 (0)              | 150 (100)        | 0 (0)             |
| Ofloxacin             | 828 (25)          | 2487 (75)          | 30 (20)          | 120 (80)          |
| Nitrofurantoin        | 1989 (60)         | 1546 (40)          | -                | -                 |

### Table 3: Antimicrobial susceptibility pattern of gram positive cocci isolated from urine

| Antimicrobials tested | Staphylococcus aureus n = 255 | Staphylococcus saprophyticus n = 200 | Staphylococcus epidermidis | Enterococcus faecalis n = 150 |
|-----------------------|-------------------------------|-------------------------------------|----------------------------|-------------------------------|
|                       | Sensitive no. (%) | Resistant no. (%) | Sensitive no. (%) | Resistant no. (%) | Sensitive no. (%) | Resistant no. (%) | Sensitive no. (%) | Resistant no. (%) |
| Amoxicillin           | -                | -                     | -                | -                     | -                | -                     | -                | -                     |
| Oxacillin             | 168 (65.9)        | 87 (34.1)             | 232 (66)         | 68 (34)               | 46 (65.7)        | 24 (34.3)             | 135 (90)        | 15 (10)                |
| Erythromycin          | 120 (47)          | 135 (53)              | 58 (29)          | 142 (71)              | 13 (18.6)        | 57 (81.4)             | 90 (60)         | 60 (40)                |
| Gatifloxacin          | 66 (26)           | 189 (74)              | 59 (29.5)        | 41 (70.5)             | 14 (20)          | 56 (80)               | -                | -                      |
| Gentamicin            | 164 (64)          | 153 (59)              | 85 (42.5)        | 115 (57.5)            | 23 (32.9)        | 40 (67.1)             | -                | -                      |
| High content gentamicin| -                | -                     | -                | -                     | -                | -                     | -                | -                      |
| High content streptomycin| -                | -                     | -                | -                     | -                | -                     | -                | -                      |
| Vancomycin            | 255 (100)         | 0 (0)                 | 200 (100)        | 0 (0)                 | 70 (100)        | 0 (0)                 | 150 (100)        | 0 (0)                  |
dehydrogenase (G6PD) deficiency in the neonates. Aminoglycosides were found to have a better profile than other groups of drugs but unfortunately these cannot be used in pregnant women. Similarly the carbapenems and glycopeptides to which all the strains of the gram negative bacilli and gram positive cocci, respectively, were found to be uniformly sensitive cannot be given in pregnancy.

The problem of selecting antibacterial treatment in pregnancy, is besides the cost benefit, the possible conflict between choosing a well-established drug that is well tolerated and empirically known to be harmless to the mother and the fetus, and choosing a drug to which there is a low level of bacterial resistance.

The drugs other than the β-lactams and nitrofurantoin, which are considered safe for the treatment of UTI in pregnant females are cotrimoxazole, fosfomycin trometamol and pivmecillinam.

Fosfomycin trometamol had been reported to have high activity against the majority of Enterobacteriaceae, but not toward the gram positive bacteria. The lack of teratogenicity in animals and apparently safe use of fosfomycin during human pregnancy indicate that the drug presents a low risk, if any, to the fetus. Because the number of first trimester human exposures is limited, however, treatment would be best delayed until after the period of organogenesis.

Cotrimoxazole (a combination of sulfamethoxazole and trimethoprim in a ratio of 5:1 or 1:2) can be used for the treatment of UTI in pregnant women if its benefits are deemed to outweigh the potential risks. Use of cotrimoxazole during pregnancy may have beneficial consequences for infants, reducing rates of low birth weight, preterm delivery and neonatal mortality. However, its use near term may lead to the displacement of bilirubin causing jaundice and kernicterus in the infant. For this reason, cotrimoxazole should not be used near term in pregnant women.

Pivmecillinam, which is a prodrug of mecillinam a β-lactam antibiotic with a novel site of action and with specific and high activity against the gram negative organisms especially Escherichia coli and other Enterobacteriaceae. The level of resistance to this drug has remained on a low level (<2% in E. coli) and its safety in pregnancy had been confirmed by clinical studies on pregnant women with UTI. Pivmecillinam is thus, an appropriate agent for use in empirical treatment of acute uncomplicated UTI in pregnancy.

The study highlights the fact, regular screening should be done for the presence of symptomatic or asymptomatic bacteriuria in pregnancy and specific guidelines should be issued for testing antimicrobial susceptibility with safe drugs in pregnant women so that these can be used for the treatment, since with the emergence of drug resistance amongst the gram positive and gram negative bacteria, the choice of drugs for the treatment of UTI is very limited. Moreover, in most of the microbiology laboratories, no specific drugs are used for the antimicrobial susceptibility testing of the urinary isolates from the pregnant females. This further shrinks the spectrum of drugs, since most of the antimicrobials which can be given in otherwise healthy individuals, may not be safe in pregnancy. However, when empirical treatment is to be started before the culture and sensitivity report can be ensured, than we suggest the use of cefoperazone-sulbactum because it is a relatively cheap drug, which safe in pregnancy, covers both the gram negative bacilli and the gram positive cocci, and as seen in our study is found to have a good sensitivity profile. We suggest that periodic surveys should be done for the prevalence and susceptibility pattern of the common pathogens causing UTI in local regions especially keeping the pregnant females as the target group.

REFERENCES
1. National Institute for Health and Clinical Excellence (NICE). Antenatal care: Routine care for the healthy pregnant women. London: NICE; 2003. Available from: http://www.nice.org.uk/nicemedia/pdf/CG062NICEguideline.pdf. [Last accessed on 2011 Mar 30].
2. Leticia AJ, Patrick JW, Henry ER. Urinary tract infections in pregnancy. Available from: http://emedicine.medscape.com/article/452604-overview. [Last accessed on 2011 Mar 4].
3. Canadian communication group. Screening for asymptomatic bacteriuria in pregnancy. Ottawa 1994.
4. Savage WE, Haji SN, Kass EH. Demographic and prognostic characteristics of bacteriuria in pregnancy. Medicine (Baltimore) 1967;46:385-407.
5. Robertson JG, Livingstone JR, Isdale MH. The management and complications of asymptomatic bacteriuria in pregnancy. Report of a study on 8,275 patients. J Obstet Gynaecol Br Commonw 1968;75:59-65.
6. Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery /low birth weight. Obstet Gynaecol 1989;73:576-82.
7. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother 2000;46 Suppl A:1-7.
8. Maclean AB. Urinary tract infection and pregnancy. In: Cattell WR, editor. Infections of the kidney and urinary tract. Oxford: Oxford University Press; 1996.
9. Nosecovicova M, Dubrava M, Cernak P, Harsanyi M. Reality of antibiotic treatment in hospitalised patients. Prakticky lekar 1994;74:275-7.
10. Nicolle LE. Short term therapy for urinary tract infection: success and failure. Int J Antimicrob Agents 2008;31 Suppl 1:S40-5.
11. Rubin RH, Beam TR, Stamm WE. An approach to evaluating antibacterial agents in the treatment of urinary tract infection. Clin Infect Dis 1992;14 Suppl 2:S246-51.
12. Collee JG, Fraser AG, Marmion BP, MacKen SA, McCartney. Practical Medical Microbiology. In: Collee JG, Miles RS, Watt B, editors. Tests for the identification of Bacteria. 14th ed. New Delhi, India: Elsevier; 2006. p. 131-49.
Rizvi, et al.: Urinary tract infections in pregnant women: A five year study

13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Wayne Pa: Clinical and Laboratory Standards Institute; M2-A9; 2006.

14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Wayne Pa: Clinical and Laboratory Standards Institute; M100-S16; 2006.

15. Rizvi M, Fatima N, Rashid M, Shukla I, Malik A, Usman A, et al. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay. J Infect Dev Ctries 2009;3:285-94.

16. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001;7:88-91.

17. Murray PR, Baron EJ, Jorgenson JH, et al. Manual of Clinical Microbiology. In: Swenson JM, Hindler JF, Jorgenson JH, editors. Special phenotypic methods for detecting antibacterial resistance. 8th ed. Washington DC: ASM Press; 2003. p. 1179.

18. Okonko IO, Ijandipe LA, Illusanya AO, Donbraye-Emmanuel OB, Ejembi J, Udeze AO, et al. Incidence of urinary tract infection (UTI) among pregnant women in Ibadan, South-Western Nigeria. Afr J Biotech 2009;8:6649-57.

19. Pais P, Khurana R, George J. Urinary tract infections: a retrospective survey of causative organisms and antibiotics prescribed in a tertiary care setting. Indian J Pharmacol 2002;34:278-80.

20. Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL and Amp C-beta-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res 2008;127:85-8.

21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 14th information supplement. Wayne Pa: Clinical and Laboratory Standards Institute; 2004:M100-S14.

22. Khan F, Shukla I, Rizvi M. The role of non-beta-lactam antimicrobials and screening for vancomycin resistance in methicillin resistant Staphylococcus aureus. Malays J Microbiol 2011;7: accepted for publication.

23. Nardiello S, Pizzella T, Ariviello R. Risk of antibacterial agents in pregnancy. Infecz Med 2002;10:8-15.

24. Peterson TF, Andriole VT. Detection, significance and therapy of bacteriuria in pregnancy. Update in the managed health care era. Infect Dis Clin North Am 1997;11:593-608.

25. Chistensen B. Which antibiotics are appropriate for treating bacteriuria in pregnancy? J Antimicrob Chemother 2000;46 Suppl 1:29-34.

26. Kremery S, Hromeej J, Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 2001;17:279-82.

27. Available from: http://www.orgyn.com/resources/genrx/D003344.asp. [Last accessed on 2011 Mar 5].

28. Cotrimoxazole improves pregnancy outcomes (Reuters health). Available from: http://aidsmeds.com/articles/1667_11308.shtml. [Last accessed on 2006 Dec 15].

29. Sulfamethoxazole and trimethoprim. Available from: http://www.medicinet.com/s_lamethoxazole_andtrimethoprim/article.htm. [Last accessed on 2011 Mar 5].

30. Graninger W. Pirmecillinam- therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003;22 Suppl 2:73-8.

How to cite this article: Rizvi M, Khan F, Shukla I, Malik A, S. Rising prevalence of antimicrobial resistance in urinary tract infections during pregnancy: Necessity for exploring newer treatment options. J Lab Physicians 2011;3:98-103.

Source of Support: Nil. Conflict of Interest: None declared.